Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 4
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau IW, Hänel M, Salwender HJ, Benner A, Raab MS, Goldschmidt H, Weinhold N. Mai EK, et al. Among authors: miah k. Blood Cancer J. 2023 Jan 4;13(1):1. doi: 10.1038/s41408-022-00772-9. Blood Cancer J. 2023. PMID: 36599831 Free PMC article. Clinical Trial.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm KM, Müller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel K, Raab MS. Giesen N, et al. Among authors: miah k. Blood. 2023 Apr 6;141(14):1685-1690. doi: 10.1182/blood.2022017789. Blood. 2023. PMID: 36608320 Clinical Trial.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Mai EK, et al. Among authors: miah k. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6. Lancet Haematol. 2024. PMID: 38302221 Free article. Clinical Trial.
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: miah k. Leukemia. 2021 Mar;35(3):809-822. doi: 10.1038/s41375-020-0976-9. Epub 2020 Jul 20. Leukemia. 2021. PMID: 32684633 Free PMC article. Clinical Trial.
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M, Jehn C, Mai EK, Bertsch U, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Raab MS, Luntz SP, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann HW, Weisel K, Duerig J, Goldschmidt H. Salwender H, et al. Among authors: miah k. Leukemia. 2021 Oct;35(10):3007-3011. doi: 10.1038/s41375-021-01298-y. Epub 2021 May 24. Leukemia. 2021. PMID: 34031532 Clinical Trial. No abstract available.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, Scheid C, Hose D, Seckinger A, Luntz S, Besemer B, Munder M, Brossart P, Glass B, Lindemann HW, Weisel K, Hanoun C, Schnitzler P, Klemm S, Goldschmidt H, Raab M, Elmaagacli A. Salwender H, et al. Among authors: miah k. Hematology. 2024 Dec;29(1):2320006. doi: 10.1080/16078454.2024.2320006. Epub 2024 Feb 26. Hematology. 2024. PMID: 38407192 Clinical Trial.
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Mai EK, et al. Among authors: miah k. Leukemia. 2021 Dec;35(12):3636. doi: 10.1038/s41375-021-01357-4. Leukemia. 2021. PMID: 34785794 Free PMC article. No abstract available.